NCT04909502 - Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

April 30, 2024

Conditions

Relapsing Forms of Multiple Sclerosis

Interventions

DRUG

EHP-101 25 mg OD

25 mg OD during the first 28 Days of the trial

DRUG

EHP-101 25 mg BID

25 mg BID during the first 28 Days of the trial

DRUG

EHP-101 50 mg OD

After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial

DRUG

EHP-101 50 mg BID

After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial

Trial Locations (4)

St. Vincent's Hospital, Melbourne

Accel Research Sites - Brain and Spine Institute of Port Orange, Port Orange

North Central Neurology Associates, Cullman

Fullerton Neurology and Headache Center, Fullerton